COMMUNIQUÉS West-GlobeNewswire

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
08/05/2025
Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reduction Full response to the IND hold on track for submission in mid-2025 Cash, cash equivalents, other [...]
Seamless Therapeutics Expands Board of Directors with Appointment of Alvin Shih
08/05/2025
Dresden, Germany, and Lexington, MA, May 8, 2025 – Seamless Therapeutics , today announced the appointment of Alvin Shih, M.D., M.B.A., as an Independent Director to its Board. Dr. Shih is an experienced drug developer [...]
ProQR Announces First Quarter 2025 Operating and Financial Results
08/05/2025
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with [...]
Conavi Medical’s Novasight Hybrid™ System Named “Product Innovation of the Year” at 2025 Minnesota Manufacturing Awards
08/05/2025
Award recognizes Novasight Hybrid™ System’s significant advance in intracoronary imaging technology TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “ [...]
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the [...]
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from [...]
Shock Top: A Bold Rebrand for a Craft Beer Icon
08/05/2025
A fresh take on the iconic brand coincides with a bold new marketing campaign PORTLAND, Ore., May 08, 2025 (GLOBE NEWSWIRE) -- Shock Top , a craft beer icon and brand by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX [...]
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
08/05/2025
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren’s disease; Phase 1 study [...]
EAACI Hong Kong Allergy School 2025: A Landmark in Global Allergy Education
08/05/2025
ZURICH, May 08, 2025 (GLOBE NEWSWIRE) -- The European Academy of Allergy & Clinical Immunology (EAACI), in partnership with the Hong Kong Institute of Allergy (HKIA), is proud to announce the inaugural EAACI Hong [...]
NewBiologix Licenses Xcell-Eng-HEK293 Cell Line to ReciBioPharm for Development and Manufacture of Adeno-Associated Virus (AAV) Therapeutics
08/05/2025
Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 cell lines for advanced therapies Complements and further expands ReciBioPharm’s AAV offering Achieves industry-leading results across [...]
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
08/05/2025
Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute [...]
Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.
08/05/2025
May 8, 2025 Announcement no. 15 Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. Interim results and a business update for the first [...]
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook
08/05/2025
COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains [...]
Swarm Oncology to present at Bio€quity Europe 2025
08/05/2025
London, U.K., May 8 2025 , Swarm Oncology Ltd. (“Swarm Oncology” or “the Company”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, today [...]
Interim report Q1 2025
08/05/2025
Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO: “ We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. [...]
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General Business Update
08/05/2025
Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first quarter 2025 results [...]
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC [...]
Zealand Pharma Announces Financial Results for the First Three Months of 2025
08/05/2025
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and [...]
Pharming Group reports first quarter 2025 financial results and provides business update
08/05/2025
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued [...]

Pages